secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001104659-26-026465
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Director Julia Haller resigns from Outlook Therapeutics board, effective March 11, 2026
--------------------------------------------------------------------------------

- Dr. Julia Haller resigned as Class II director, also serving on Nominating and Corporate Governance Committee.
- Board accepted resignation on March 6, 2026, effective March 11, with board size reduced to nine.
- Resignation not due to any dispute with company; she cited new CEO duties at Wills Eye Hospital.
- Company thanked Dr. Haller for her contributions during her tenure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926026465/0001104659-26-026465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926026465/tm268371d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-026465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer